Redeye provides an update following Heliospectra’s amended Q4'22 report, in which order intake was significantly increased from SEK7.7m to 14.3m. We further view the appointment of Bonny Heeren as permanent CEO positively, as he has been the driving force behind the cost-cut program and the transformation of Heliospectra in 2022. Heliospectra enters 2023 with a lighter cost base, a new product range, and the ambition to reach break even by the end of 2023. We have made some minor adjustments to our estimates, lowering expectations for H1’23 but increasing our mid-term expectations. However, our valuation remains intact with a base case fair value at SEK1.7 per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/